Alkermes Plc (NASDAQ: ALKS) is considered one of the best breakout stocks to invest in. Positive topline clinical trial data for its narcolepsy treatment, Alixorexton, was delivered on November 12, leading analysts at TD Cowen to reiterate a Buy rating with a $40 price target. Alixorexton showed efficacy in phase 2 studies for narcolepsy type 1, type 2, and idiopathic hypersomnia. 95% of patients completed the 8-week period with a tolerable safety profile and met primary endpoints for improvements compared to placebo. Alkermes plans to start a phase 3 program in the first quarter of next year.

Read more at Yahoo Finance: TD Cowen Asserts Buy Rating as Alkermes plc (ALKS) Delivers Topline Results for Narcolepsy Treatment